The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2024
Filed:
Mar. 03, 2022
Applicant:
Eyepoint Pharmaceuticals, Inc., Watertown, MA (US);
Inventors:
Kevin Peters, Cincinnati, OH (US);
Robert Shalwitz, Bexley, OH (US);
John Janusz, West Chester, OH (US);
Alexander Smith, Apex, NC (US);
Assignee:
EYEPOINT PHARMACEUTICALS, INC., Watertown, MA (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/433 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/538 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61K 47/69 (2017.01); A61P 27/00 (2006.01); A61P 27/02 (2006.01); C07D 277/28 (2006.01); C07D 277/30 (2006.01); C07D 277/56 (2006.01); C07D 277/60 (2006.01); C07D 277/64 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 417/12 (2013.01); A61K 9/0019 (2013.01); A61K 9/0051 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/538 (2013.01); A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61K 47/6951 (2017.08); A61P 27/00 (2018.01); A61P 27/02 (2018.01); C07D 277/28 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 277/60 (2013.01); C07D 277/64 (2013.01); C07D 417/04 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01);
Abstract
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.